ArticleMolecular diversity2026
DeepMice: a novel protein-ligand molecular docking model based on multilevel mapping modules.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Our study presents DeepMice, a novel artificial intelligence-based molecular docking framework designed to predict protein-ligand binding conformations with improved accuracy. DeepMice's scoring function utilizes a graph transformer network (GTN) as its backbone. It transforms residue-level representations into atomic-level representations, enhancing representation precision. A multilevel mapping module is incorporated to reduce the graph model's size and computational complexity. Subsequently, the mixture density network (MDN) is employed to further realize scoring prediction. In terms of conformational search, DeepMice employs a hybrid strategy combining global heuristic search and local gradient-based optimization. The process initiates with a global exploration using the Differential Evolution (DE) algorithm, followed by local refinement via the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm. This combined approach enhances conformational search efficiency. Performance tests on the DEKOIS2.0 and DUD-E datasets showed that DeepMice outperformed existing virtual screening technologies such as Glide SP and RTMScore in terms of area under the receiver operating characteristic curve (AUROC), boltzmann-enhanced discrimination of receiver operating characteristic (BEDROC), and enrichment factor (EF) values. In particular, DeepMice demonstrates advanced molecular docking capabilities in the CASF-2016 standard test set. In addition, DeepMice considers the multiscale structure of proteins, optimizing the conformation scoring process and improving docking efficiency. In summary, DeepMice is an efficient and accurate molecular docking model, which is expected to accelerate the process of new drug research and development. The program based on the DeepMice model, which is now freely available at https://www.deepmice.com , provides a powerful tool for drug discovery.
Indexed as
Identifiers
41046490What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.